Novavax (XSWX:NVAX) Treasury Stock: CHF-89.8 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:NVAX Novavax Inc XSWX:NVAX
46 GF Score
Price CHF7.24
GF Value CHF2.58
! 6 Warning Signs
View Full Analysis

What is Novavax Treasury Stock?

Novavax XSWX:NVAX +9.21% 46 Treasury Stock is CHF-89.8 Mil as of Jun. 2026. GuruFocus rates XSWX:NVAX with a GF Score™ of 46/100 and a GF Value™ of CHF2.58. The stock has 6 warning signs investors should review.

Treasury stock is the portion of shares that a company keeps in their own treasury. Novavax's treasury stock for the quarter that ended in Jun. 2026 was CHF-89.8 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.

Novavax Treasury Stock Historical Data

* Premium members only.

The historical data trend for Novavax's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novavax Treasury Stock Chart

Novavax Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Treasury Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only -78.38 -84.46 -79.79 -85.46 -82.10

Novavax Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Treasury Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -83.32 -81.73 -82.10 -88.43 -89.82
XSWX:NVAX
46GF Score
Novavax Inc XSWX:NVAX
Treasury Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Novavax Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.

Frequently Asked Questions Learn more about Treasury Stock →
What does a Treasury Stock of CHF-89.8 Mil mean?
Novavax (XSWX:NVAX) has a Treasury Stock of CHF-89.8 Mil as of Jun. 2026. Treasury stock is a contra-equity item that records the amount of stock not issued to shareholders. View historical data for Novavax and its competitors.
Is Novavax's Treasury Stock too high?
Novavax's current Treasury Stock is CHF-89.8 Mil. Overall, Novavax has a GF Score™ of 46/100, reflecting its overall financial health beyond just this single metric.
How does Novavax's Treasury Stock compare to JBIO and AVLN?
Novavax's Treasury Stock of CHF-89.8 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Treasury Stock for a Biotechnology company?
A good Treasury Stock depends on the Biotechnology industry context. However, Treasury Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Treasury Stock mean?
A high Treasury Stock can signal that a stock is expensive relative to its fundamentals. Treasury stock is a contra-equity item that records the amount of stock not issued to shareholders. View historical data for Novavax and its competitors. Novavax's current Treasury Stock is CHF-89.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novavax stock overvalued right now?
Novavax (XSWX:NVAX) has a current Treasury Stock of CHF-89.8 Mil. The stock's GF Value™ is CHF2.58, compared to a current price of CHF7.24 — trading 180.7% above its estimated fair value. The current Treasury Stock is CHF-89.8 Mil. Novavax's overall GF Score™ is 46/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Treasury Stock calculated?
Treasury Stock is calculated from a company's financial statements. For Novavax (XSWX:NVAX), the current Treasury Stock is CHF-89.8 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Novavax (XSWX:NVAX) Overvalued in 2026?

Based on GuruFocus' analysis, Novavax stock appears to be overvalued. The current stock price of CHF7.24 is trading 180.7% above its estimated GF Value™ of CHF2.58.

Key valuation signals for XSWX:NVAX:

  • Treasury Stock: CHF-89.8 Mil
  • GF Value™: CHF2.58 vs. price of CHF7.24 (180.7% above fair value)
  • GF Score™: 46/100 with 6 warning signs

No single metric tells the full story. See the XSWX:NVAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Novavax Business Description

Address 21 Firstfield Road, Gaithersburg, MD, USA, 20878
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.
46GF Score

Get the complete analysis for XSWX:NVAX

Treasury Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF7.24
Price
CHF2.58
GF Value